long intergenic non-protein coding RNA 1603Genealiases: []
Q-omics provides the consensus-scored LINC01603 profile across patient tissues and cancer cell-line models. LINC01603 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LINC01603 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LINC01603 RNA expression shows 7,258 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight CHOL, HNSC, and ESCA as cancer lineages where LINC01603 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01603 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01603 survival associations across molecular data types. LINC01603 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01603 RNA expression–survival associations across cancer types. High LINC01603 expression shows unfavorable associations in CHOL, DLBC and UVM, but favorable associations in HNSC, UCS and SKCM. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CHOL as the clearest survival context for LINC01603 RNA expression.
This table summarizes LINC01603 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01603. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01603 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, BRCA, STAD and LUAD. The HNSC box plot shows higher LINC01603 RNA expression in tumor versus normal tissue (log2 FC = +0.055, t-test p < 0.001).
This table shows molecular features associated with LINC01603 in patient tissues and cancer cell lines. In patient samples, LINC01603 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
